- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:30 | Belite Bio stock soars to all-time high of $70.4 amid robust growth | 1 | Investing.com | ||
| 21:22 | Belite Bio-Aktie erreicht Allzeithoch von 70,4 US-Dollar | 2 | Investing.com Deutsch | ||
| 11:03 | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| So | Belite Bio, Inc: Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 28.10. | Belite Bio-Aktie erreicht Allzeithoch von 67,6 US-Dollar | - | Investing.com Deutsch | ||
| 28.10. | Belite Bio stock soars to all-time high of $67.6 amid robust gains | 1 | Investing.com | ||
| 18.10. | Belite Bio stock soars to all-time high of $56.62 | 1 | Investing.com | ||
| 18.10. | Belite Bio-Aktie erreicht Allzeithoch von 56,62 US-Dollar | 2 | Investing.com Deutsch | ||
| 10.10. | Belite Bio-Aktie erreicht Allzeithoch von 55,68 US-Dollar | 2 | Investing.com Deutsch | ||
| 10.10. | Belite Bio stock soars to all-time high of $55.68 | 1 | Investing.com | ||
| 03.10. | Belite Bio-Aktie erreicht Allzeithoch von 50,69 US-Dollar | 3 | Investing.com Deutsch | ||
| 03.10. | Belite Bio stock soars to all-time high of $50.69 | 1 | Investing.com | ||
| 01.10. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 03.09. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.09. | Belite Bio names Hendrik P. N. Scholl as chief medical officer | 1 | Seeking Alpha | ||
| 01.09. | Belite Bio Appoints Hendrik Scholl As Chief Medical Officer | 1 | RTTNews | ||
| 01.09. | Belite Bio, Inc: Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer | 521 | GlobeNewswire (Europe) | Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease
SAN DIEGO, Sept.... ► Artikel lesen | |
| 13.08. | Belite Bio GAAP EPS of -$0.26 in-line | 1 | Seeking Alpha | ||
| 09.08. | Belite Bio EPS of -$0.31 misses by $0.05 | 1 | Seeking Alpha | ||
| 09.08. | Belite Bio, Inc: Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update | 646 | GlobeNewswire (Europe) | Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARGENX | 539,00 | -1,93 % | argenx SE: argenx Reports Third Quarter 2024 Financial Results and Provides Business Update | $573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call... ► Artikel lesen | |
| EVOTEC | 8,100 | +13,37 % | Evotec Aktie: Wochen der Wahrheit? | Bei der Evotec Aktie haben am Donnerstag und Freitag zum einen Gewinnmitnahmen nach dem jüngsten Kursanstieg das Bild geprägt. Aber - zumindest am Donnerstag - blieben zudem Rückkäufe der Evotec Aktie... ► Artikel lesen | |
| QIAGEN | 40,170 | +1,11 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
| VIKING THERAPEUTICS | 59,00 | -13,39 % | AKTIONÄR-Depotwert Gubra: Bald wie Viking Therapeutics? | Die Aktie von Viking Therapeutics hat in der Vorwoche massive Kursgewinne verzeichnet. Vor allem die Aussicht auf weiteren Studiendaten zum Adipositas-Hoffnungsträger VK2735 Anfang November sowie die... ► Artikel lesen | |
| BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,300 | +0,29 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
| DISC MEDICINE | 59,41 | +28,18 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,56 | -0,20 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,070 | +7,96 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 33,060 | -0,18 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 45,130 | +7,20 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
| DYNE THERAPEUTICS | 28,820 | +0,03 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| ARCELLX | 87,83 | +2,59 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
| BEAM THERAPEUTICS | 24,730 | +8,46 % | Beam Therapeutics' Earnings: A Preview | ||
| RECURSION PHARMACEUTICALS | 6,625 | +2,95 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,79 % bei einem Aktienkurs von 63,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.
